PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2099521
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2099521
According to Mordor Intelligence, the freeze drying equipment and services market size is expected to grow from USD 3.20 billion in 2025 to USD 3.47 billion in 2026 and is forecast to reach USD 5.21 billion by 2031 at 8.45% CAGR over 2026-2031.

This report is Segmented by Modality (Equipment, Services), Scale of Operation (Laboratory, Pilot, Industrial), Application (Pharmaceuticals, Biotechnology, Food Processing, Nutraceuticals, Others), End User (Pharma/Biotech Companies, Food Processors, Academic Institutes, Cdmos, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).
The freeze drying equipment and services market is recording stronger demand from biologics, as lyophilization is shifting from a supporting process step to a core production requirement. Monoclonal antibodies, antibody-drug conjugate therapies, and messenger RNA-based vaccines often require freeze drying when liquid formats do not provide sufficient ambient-temperature stability. Lyophilization of messenger RNA lipid nanoparticles is becoming a critical formulation route for next-generation therapeutics, with growing use of Quality by Design and Process Analytical Technology in regulatory work. Buyers are increasingly specifying Process Analytical Technology integration at the purchase stage because retrofitting a unit later is difficult in a Good Manufacturing Practice setting. As a result, contract development and manufacturing organizations competing for large-molecule programs are favoring open-architecture systems that support third-party Process Analytical Technology tools and broader process control requirements.
The freeze drying equipment and services market is benefiting from wider adoption in premium food and nutraceutical products. Freeze-dried food has moved beyond military and survival applications and is now part of mainstream premium retail demand. In nutraceuticals, probiotics, botanical extracts, and sensitive proteins often require freeze drying because heat-based methods can damage the active compounds that define product value. Clean-label snacking and functional nutrition trends are expanding the installation base for food-grade lyophilizers beyond traditional fruit and vegetable processing. This segment follows a different buying pattern than pharmaceutical demand, as cleanroom requirements are lower, while price pressure and throughput requirements are higher.
High capital costs remain a key barrier to expansion in the freeze drying equipment and services market. A large pharmaceutical-grade production freeze dryer can cost USD 1 million to more than USD 5 million before installation, qualification, and validation costs. This cost is significantly higher than that of spray dryers or fluidized bed systems with similar throughput requirements. For generic injectable manufacturers and emerging-market contract development and manufacturing organizations (CDMOs), this cost profile extends return periods and can delay investment decisions by several years. Higher financing costs from 2022 through 2025 are expected to make procurement more difficult for smaller operators, especially where price-sensitive end products limit the scope for premium processing choices.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Equipment is expected to hold 78.12% of the freeze drying equipment and services market in 2025, reflecting the capital-intensive nature of lyophilization build-outs. Tray-style systems remain the preferred configuration across pharmaceutical and food applications because they support batch uniformity and automated loading. Manifold and rotary systems continue to serve laboratory and nutraceutical applications, where flexibility is more important than maximum throughput.
Replacement demand is also supporting equipment purchases, as older units in Europe face refrigerant-related compliance pressure. Retrofit costs of up to EUR 80,000 (USD 91,498.80) for older units have encouraged some operators to choose full replacement over partial upgrades. Services are projected to grow faster, at a CAGR of 9.53% through 2031, driven by long-term requirements for validation, calibration, maintenance, training, and outsourced lyophilization support.
Industrial-scale systems are expected to account for 48.45% of the freeze drying equipment and services market size in 2025, as commercial pharmaceutical and food facilities require large batch capacity and consistent throughput. Major biopharma companies, contract development and manufacturing organizations (CDMOs), and food processors typically purchase these systems to improve shelf utilization and turnaround time. Pilot-scale units remain important because they connect development work with commercial manufacturing.
Large-scale demand remains visible through supplier investments. GEA is expected to inaugurate its EUR 80 million (USD 91.50 million) pharmaceutical technology center in Elsdorf, Germany, in February 2026, combining research, production, and digital workflows in a 40,000+m2 CO2-neutral site. Laboratory-scale freeze dryers are projected to grow at a CAGR of 10.67% through 2031, supported by contract research organizations (CROs), academic institutes, and pharmaceutical research and development (R&D) teams working on formulation and scale-up.
North America is expected to hold 42.56% of the freeze drying equipment and services market in 2025, making it the largest regional contributor. The region benefits from the scale of the US biopharmaceutical manufacturing base and strong demand for lyophilized injectables. FDA oversight of process validation and freeze drying control continues to support demand for advanced equipment, process analytical technology (PAT) integration, and revalidation services. PCI Pharma Services' planned commissioning in April 2026 of a twin 40 m2 lyophilizer line in Bedford, New Hampshire, with an annual capacity of 33 million vials, highlights sustained regional investment.
Europe remains the second-largest regional market in the freeze drying equipment and services market and has the deepest concentration of pharmaceutical-grade equipment suppliers. The region includes major companies such as GEA Group, Syntegon, Martin Christ, IMA S.p.A., OPTIMA, and ZIRBUS. Germany serves as both a manufacturing hub and a major end-user center, supported by GEA's EUR 80 million (USD 91.50 million) Elsdorf facility, scheduled to open in February 2026. Compliance with European Union Good Manufacturing Practice (EU GMP) Annex 1 is driving investment in sterilization validation and automated loading systems across European facilities.
Asia-Pacific is the fastest-growing region in the freeze drying equipment and services market, with a projected CAGR of 12.56% through 2031. China is recording strong local demand as biosimilar, antibody-drug conjugate (ADC), and messenger ribonucleic acid (mRNA) manufacturing scale up. Domestic manufacturers are strengthening their position in standard pharmaceutical systems, while imported brands continue to lead the higher-end biopharmaceutical tier. India is benefiting from export-focused contract development and manufacturing organization (CDMO) expansion, sterile dosage growth, and continued manufacturing modernization, while the Middle East, Africa, and South America remain smaller but are seeing opportunities from local vaccine manufacturing and lower cold-chain dependence in Brazil, South Africa, Saudi Arabia, and the UAE.